|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0009450,
umls-concept:C0015737,
umls-concept:C0019704,
umls-concept:C0020517,
umls-concept:C0021311,
umls-concept:C0035647,
umls-concept:C0036043,
umls-concept:C0042210,
umls-concept:C0085432,
umls-concept:C0205251,
umls-concept:C0681850,
umls-concept:C1171370,
umls-concept:C1257890,
umls-concept:C1272753,
umls-concept:C1414406,
umls-concept:C1550501,
umls-concept:C1706203,
umls-concept:C1882071,
umls-concept:C2349001,
umls-concept:C2697811
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1993-12-28
|
|
pubmed:abstractText |
Recombinant gp160 derived from human immunodeficiency virus type 1 (HIV-1)IIIB and produced in mammalian tissue culture cells using a vaccinia virus expression system (rgp160-mam) was evaluated as a vaccine in combination with alum and deoxycholate adjuvant. Sixty low-risk, uninfected subjects received 12.5 micrograms, 50.0 micrograms, or adjuvant control at 0, 1, 6, and 12 months in a randomized, double-blind dose-escalation study. A single injection of 200 micrograms of vaccine was given at 18 months in an open study to 9 vaccines who had received 50 micrograms. The vaccine was safe. Six of 16 subjects receiving 50 micrograms developed neutralizing antibody to HIV-1IIIB. Seven of the 9 boosted with 200 micrograms of vaccine at 18 months developed neutralizing antibodies. Lymphocyte proliferation to rgp160-mam and baculovirus-derived rgp160 and rgp120 was induced in both groups (12.5 and 50.0 micrograms) and appeared after the first dose. Further studies with higher doses of rgp160-mam and vaccines derived from other strains of HIV-1 are warranted.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/AIDS Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Antinuclear,
http://linkedlifedata.com/resource/pubmed/chemical/Gene Products, env,
http://linkedlifedata.com/resource/pubmed/chemical/HIV Envelope Protein gp160,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Precursors,
http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, Synthetic
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0022-1899
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
168
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
1387-95
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:8245523-AIDS Vaccines,
pubmed-meshheading:8245523-Adjuvants, Immunologic,
pubmed-meshheading:8245523-Adolescent,
pubmed-meshheading:8245523-Adult,
pubmed-meshheading:8245523-Aged,
pubmed-meshheading:8245523-Animals,
pubmed-meshheading:8245523-Antibodies, Antinuclear,
pubmed-meshheading:8245523-Cells, Cultured,
pubmed-meshheading:8245523-Double-Blind Method,
pubmed-meshheading:8245523-Female,
pubmed-meshheading:8245523-Gene Products, env,
pubmed-meshheading:8245523-Glycosylation,
pubmed-meshheading:8245523-HIV Envelope Protein gp160,
pubmed-meshheading:8245523-HIV-1,
pubmed-meshheading:8245523-Humans,
pubmed-meshheading:8245523-Lymphocytes,
pubmed-meshheading:8245523-Male,
pubmed-meshheading:8245523-Middle Aged,
pubmed-meshheading:8245523-Protein Precursors,
pubmed-meshheading:8245523-Safety,
pubmed-meshheading:8245523-Vaccines, Synthetic,
pubmed-meshheading:8245523-Vero Cells
|
|
pubmed:year |
1993
|
|
pubmed:articleTitle |
Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network.
|
|
pubmed:affiliation |
Dept. of Medicine, St. Louis University School of Medicine, MO 63104.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial
|
